Privately-held InSight Biopharmaceuticals Ltd. has been a player in the biotechnology field since 1995. It is active in the development of biosimilars and innovative biologics and diagnostics. Over the past 15 years InSight has established strategic alliances and developed technologies for manufacturing a wide spectrum of recombinant protein-based generic biopharmaceuticals (biogenerics). These technologies were designed to yield high quality products while being highly efficient, cost-effective, and competitive, thus enabling manufacturing for a significant stake of target markets in relatively small GMP local plants. Having successfully commercialized these technologies, InSight is continuously upgrading its position as a biogenerics developer, both for developing countries and for the highly regulated (ICH) markets. InSight is extensively involved in the development of front-edge biopharmaceuticals and has an impressive track record of scientific discoveries. Using its drug discovery platforms, InSight's scientists were the first to clone the gene coding for human Heparanase (hpa), a key enzyme in cancer and inflammatory processes. Based on its discoveries, inventions and strong intellectual property, InSight is focused on the development of novel anti-cancer drugs and cancer diagnostics.